Management and Outcomes of Metastatic and Recurrent Malignant Phyllodes Tumors of the Breast : A Systematic Literature Review

Article Article scientifique Revue de la littérature Management and Outcomes of Metastatic and Recurrent Malignant Phyllodes Tumors of the Breast : A Systematic Literature Review eng 2023-07-03 2023-07 author Samii Elaheh Anouk Faculty of Medicine, University of Geneva, Geneva, Switzerland. 879278 author Hurni Yannick 0000-0002-0369-615X Department of Gynecology and Obstetrics, Valais Hospital, Sion, Switzerland. author Huber Daniela 0000-0002-9082-9749 Department of Gynecology and Obstetrics, Valais Hospital, Sion, Switzerland.,Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland. 788725 Département de Pédiatrie, Gynécologie et Obstétrique (PETRI) Daniela Emanuela Huber 191-200 10.4274/ejbh.galenos.2023.2023-3-2 37415652 2587-0831 PMC10320634 https://eurjbreasthealth.com/articles/doi/ejbh.galenos.2023.2023-3-2 To summarize the evidence on the current management and outcomes for metastatic and recurrent malignant phyllodes tumors (MPTs) of the breast. A systematic literature review of all cases of metastatic or recurrent MPTs of the breast published between 2010 and 2021 was performed. In total, 66 patients from 63 articles were included. Fifty-two (78.8%) had distant metastatic disease (DMD subgroup), and 21 (31.8%) showed locoregional recurrent/progressive disease (LRPR subgroup). Locoregional recurrences in patients with no distant metastases were treated with surgical excision in all cases. Radiotherapy was administered in 8/21 cases (38.1%) and was combined with chemotherapy in 2/21 cases (9.5%). Metastatic disease was managed through metastases surgical excision, chemotherapy, radiotherapy, or a combination of these three in 84.6% of cases, while the remaining patients received no oncological treatments. Chemotherapy was proposed in 75.0% of cases. Anthracycline and alkylating agent-based combination regimens were most frequently administered. The median survival time was 24 (2.0-152.0) months, and 72.0 (2.5-98.5) months in the DMD and LRPR subgroups, respectively. Management of recurrent or metastatic MPTs is challenging. Surgery is the fundamental approach, but the use of adjuvant radio- and chemo-therapy remains controversial due to the lack of scientific evidence. Further studies and international registers are needed to implement new and more efficient treatment strategies. Phyllodes tumor Adjuvant treatment Breast cancer Local relapse Metastatic Recurrence Dewey 618 58 Département de pédiatrie, gynécologie et obstétrique 223 false European journal of breast health 19 3 623cce24-30dc-4b90-adec-9bf2e973202f Article (Published version) Public ejbh-19-191.pdf 756555 application/pdf 768ecb05ab1690e6bf2e9adaab9eb1c5af5d7503673fa10a382f437a292a2129 openAccess Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Management and Outcomes of Metastatic and Recurrent Malignant Phyllodes Tumors of the Breast : A Systematic Literature Review	European journal of breast health			2023	53	326

Archive ouverte UNIGE

Samii, Elaheh Anouk